Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma.

Yang, Sheng-Hsiang

Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma. [electronic resource] - Journal of the Chinese Medical Association : JCMA Jul 2015 - 400-7 p. digital

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

1728-7731

10.1016/j.jcma.2015.02.005 doi


Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--therapeutic use
Combined Modality Therapy
Female
Fluorodeoxyglucose F18
Humans
Induction Chemotherapy
Lymphoma, Large B-Cell, Diffuse--mortality
Male
Mediastinal Neoplasms--mortality
Middle Aged
Positron-Emission Tomography
Rituximab--therapeutic use